Q-omics provides the consensus-scored ZFP28 profile across patient tissues and cancer cell-line models. ZFP28 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZFP28 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZFP28 RNA expression shows 21,161 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where ZFP28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP28 survival associations across molecular data types. ZFP28 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP28 RNA expression–survival associations across cancer types. High ZFP28 expression shows unfavorable associations in LGG, but favorable associations in HNSC, LUAD, PAAD, KIRC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZFP28 RNA expression.
This table summarizes ZFP28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZFP28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP28 shows lower tumor expression in KIRC, BLCA, THCA, UCEC, HNSC and KICH. The KIRC box plot shows higher ZFP28 RNA expression in normal versus tumor tissue (log2 FC = −0.851, t-test p < 0.001).
This table shows molecular features associated with ZFP28 in patient tissues and cancer cell lines. In patient samples, ZFP28 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
